|
Company data displayed is for sample purposes only and may not reflect the most current information available on Emerging Markets Information Service (EMIS).
Indofarma (Persero) Tbk, PT
Main Activities: Chemical Manufacturing
 |
Please check the full coverage of information what EMIS can offer you. | SEE SAMPLE |
Company Information |
|
Full name Indofarma (Persero) Tbk, PT Headquarters Jl Indofarma No 1, Cikarang Barat; Cikarang; West Java; 17530 |
Status: Listed Legal Form: Public Limited Company Operational Status: Operational ISIN CODE : ID1000068406 Financial Auditors: Husni, Mucharam & Rasidi (2011) Incorporation Date: January 2, 1996 Total Employees: 1,641 Tel: (62 21) 88323971 |
|
Company Description |
| PT Indofarma (Persero) Tbk (INAF), which is a state-owned enterprise, is a producer of pharmaceuticals and health products. The company started commercial operations in 1983. The company's products are marketed both domestically and internationally. The Company engaged in manufactures markets and distributes pharmaceuticals products, including ethical and OTC products. Besides, the Company also markets and distributes health products. The Company's ethical products include generic medicines and | ||
|
||
Company Analysis |
| According to the Consolidated - Non-Audited financial statement for the first three cumulated quarters of 2012, total net operating revenues increased with 1.01%, from IDR 695,150,787 thousands to IDR 702,169,597 thousands. Operating result increased from IDR 45,456,244 thousands to IDR 47,724,840 thousands which means 4.99% change. The results of the period increased 24.44% reaching IDR 20,033,018 thousands at the end of the period against IDR 16,098,392 thousands last year. Return on equity (Net income/Total equity) went from 2.74% to 3.18%, the Return On Asset (Net income / Total Asset) went from 1.37% to 1.73% and the Net Profit Margin (Net Income/Net Sales) went from 2.32% to 2.85% when compared to the same period of last year. The Debt to Equity Ratio (Total Liabilities/Equity) was 84.16% compared to 99.47% of last year. Finally, the Current Ratio (Current Assets/Current Liabilities) went from 1.42 to 1.57 when compared to the previous year. |
Key Executives |
|
|||||
|
|||||
|
|||||
|
|||||
|
|||||
|
|||||
Companies with Similar Main Activities |
FULL COMPANY PROFILE
|
|
2012 Y (cons) |
2012 Q3C (cons) |
|
 | ||
| Audited | Non-Audited | |
| ||
| WVB Company Financials | WVB Company Financials | |
| ||
| Unit | Thousands | Thousands |
| ||
Balance Sheet
| ||
Total Assets |
1,188,618,752 |
1,158,773,504 |
| ||
Current Assets |
777,629,120 |
752,593,792 |
| ||
Total Liabilities |
538,518,208 |
529,548,096 |
| ||
Shareholders Equity |
650,102,208 |
629,226,867 |
| ||
Current Liabilities |
369,863,744 |
478,991,456 |
| ||
| * All the accounts are in IDR. | ||
Income Statement
| ||
Total Operating Revenue |
1,157,496,437 |
702,169,597 |
| ||
Operational Profit (Loss) |
82,142,672 |
47,724,840 |
| ||
Net Profit (Loss) |
42,384,956 |
20,033,018 |
| ||
| * All the accounts are in IDR. | ||
Ratios
| Profitability Ratios | ||
| ||
Return on Assets (ROA) |
3.57% |
1.73% |
| ||
Annualised Return on Assets (ROA) |
3.57% |
2.31% |
| ||
Return on Equity (ROE) |
6.52% |
3.18% |
| ||
Annualised Return on Equity (ROE) |
6.52% |
4.24% |
| ||
Return on Sales (ROS) |
3.67% |
2.86% |
| ||
Return on Capital |
5.51% |
3.18% |
| ||
Gross Profit Margin |
32.46% |
38.67% |
| ||
Operating Profit Margin |
8.17% |
9.23% |
| Efficiency Ratios | ||
| ||
Accounts Receivable Turnover |
4.84x |
2.16x |
| ||
Inventory Turnover |
4.84x |
2.07x |
| ||
Current asset turnover |
1.49x |
0.93x |
| ||
Fixed-asset turnover |
2.81x |
1.73x |
| ||
Asset Turnover |
0.97x |
0.61x |
| Valuation figures and ratios | ||
| ||
Earning Before Interests and Taxes (EBIT) |
84,188,920 |
51,265,740 |
| ||
EBITDA |
95,849,557 |
65,381,197 |
| ||
Enterprise value |
1,022,345,635 |
926,846,683 |
| ||
Enterprise Value / EBITDA |
10.67 |
14.18 |
| ||
Bookvalue (BV) |
994,130,192 |
875,749,088 |
| ||
Net Cash |
-174,960,944 |
-456,469,752 |
| Liquidity Ratios | ||
| ||
Current Ratio |
210.25% |
157.12% |
| ||
Quick ratio |
166.63% |
113.66% |
| ||
Doom's day ratio |
52.7% |
4.7% |
| Leverage Ratios | ||
| ||
Leverage ratio |
182.84% |
184.16% |
| ||
Interest Coverage Ratio |
402.32% |
366.86% |
| ||
Debt to equity |
82.84% |
84.16% |
| ||
Debt to total assets |
45.31% |
45.7% |
| ||
Long Term Debt to Capital |
35.24% |
14.02% |
| ||
Debt / Enterprise Value |
19.02% |
30.54% |
| Market ratios | ||
| ||
Market Capitalization/EBITDA |
10.67 |
10.19 |
| ||
Price/Book Ratio |
1.03 |
0.76 |
| ||
Market Cap / Net cash |
-5.85 |
-1.46 |
| Trend Ratios | ||
| ||
Revenue Trend |
96.06% |
100.92% |
| ||
Net Income Trend |
114.8% |
124.44% |
| ||
Operating Income Trend |
90.51% |
110.79% |
| ||
 |